Saltar al contenido
Merck

Side effect profile of 5-HT treatments for Parkinson's disease and L-DOPA-induced dyskinesia in rats.

British journal of pharmacology (2014-09-02)
D Lindenbach, N Palumbo, C Y Ostock, N Vilceus, M M Conti, C Bishop
RESUMEN

Treatment of Parkinson's disease (PD) with L-DOPA eventually causes abnormal involuntary movements known as dyskinesias in most patients. Dyskinesia can be reduced using compounds that act as direct or indirect agonists of the 5-HT1 A receptor, but these drugs have been reported to worsen PD features and are known to produce '5-HT syndrome', symptoms of which include tremor, myoclonus, rigidity and hyper-reflexia. Sprague-Dawley rats were given unilateral nigrostriatal dopamine lesions with 6-hydroxydopamine. Each of the following three purportedly anti-dyskinetic 5-HT compounds were administered 15 min before L-DOPA: the full 5-HT1 A agonist ±-8-hydroxy-2-dipropylaminotetralin (±8-OH-DPAT), the partial 5-HT1 A agonist buspirone or the 5-HT transporter inhibitor citalopram. After these injections, animals were monitored for dyskinesia, 5-HT syndrome, motor activity and PD akinesia. Each 5-HT drug dose-dependently reduced dyskinesia by relatively equal amounts (±8-OH-DPAT ≥ citalopram ≥ buspirone), but 5-HT syndrome was higher with ±8-OH-DPAT, lower with buspirone and not present with citalopram. Importantly, with or without L-DOPA, all three compounds provided an additional improvement of PD akinesia. All drugs tempered the locomotor response to L-DOPA suggesting dyskinesia reduction, but vertical rearing was reduced with 5-HT drugs, potentially reflecting features of 5-HT syndrome. The results suggest that compounds that indirectly facilitate 5-HT1 A receptor activation, such as citalopram, may be more effective therapeutics than direct 5-HT1 A receptor agonists because they exhibit similar anti-dyskinesia efficacy, while possessing a reduced side effect profile.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Cloruro de sodio, for molecular biology, DNase, RNase, and protease, none detected, ≥99% (titration)
Sigma-Aldrich
Ácido L-ascórbico, powder, suitable for cell culture, γ-irradiated
Sigma-Aldrich
Ácido L-ascórbico, BioXtra, ≥99.0%, crystalline
Sigma-Aldrich
Sodium chloride solution, 5 M in H2O, BioReagent, for molecular biology, suitable for cell culture
Sigma-Aldrich
Sodium chloride solution, 0.9% in water, BioXtra, suitable for cell culture
Sigma-Aldrich
Hydrobromic acid, ACS reagent, 48%
Sigma-Aldrich
Cloruro de sodio, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, ≥99%
Sigma-Aldrich
Ácido L-ascórbico, suitable for cell culture, suitable for plant cell culture, ≥98%
SAFC
Sodium chloride solution, 5 M
Sigma-Aldrich
Hydrobromic acid, reagent grade, 48%
Sigma-Aldrich
6-Hydroxydopamine hydrochloride, ≥97% (titration), powder
Sigma-Aldrich
Ácido L-ascórbico, reagent grade, crystalline
Sigma-Aldrich
Cloruro de sodio, BioXtra, ≥99.5% (AT)
Sigma-Aldrich
Hydrobromic acid solution, 33 wt. % in acetic acid
USP
Ácido L-ascórbico, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Cloruro de sodio, JIS special grade, ≥99.5%
Sigma-Aldrich
Hydrogen bromide solution, 33 wt. % in acetic acid
Sigma-Aldrich
Sodium chloride solution, BioUltra, for molecular biology, ~5 M in H2O
Sigma-Aldrich
Hydrobromic acid, 48 wt. % in H2O, ≥99.99%
Sigma-Aldrich
Cloruro de sodio, BioUltra, for molecular biology, ≥99.5% (AT)
Supelco
Ácido L-ascórbico, analytical standard
Sigma-Aldrich
Cloruro de sodio, 99.999% trace metals basis
Sigma-Aldrich
6-Hydroxydopamine hydrobromide, 95%
Sigma-Aldrich
Ácido L-ascórbico, 99%
Sigma-Aldrich
Ácido L-ascórbico, reagent grade
Supelco
Ácido L-ascórbico, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Sodium chloride solution, 5 M
Sigma-Aldrich
Ácido L-ascórbico, meets USP testing specifications
Sigma-Aldrich
Ácido L-ascórbico, ACS reagent, ≥99%
Sigma-Aldrich
Cloruro de sodio, SAJ first grade, ≥99.0%